Relapsed/Refractory Diffuse Large B Cell Lymphoma research hub

C4971006: A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION

This study looks at a new combination of medicines for adults with a type of blood cancer called Diffuse Large B Cell Lymphoma that has come back or is hard to treat. It checks how safe the medicines are and how well they work.